<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578223</url>
  </required_header>
  <id_info>
    <org_study_id>KB/138/217</org_study_id>
    <nct_id>NCT04578223</nct_id>
  </id_info>
  <brief_title>Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension</brief_title>
  <acronym>PAPAYA</acronym>
  <official_title>Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Health Centre Otwock</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Prostacyclin analogues (epoprostenol, treprostinil and iloprost) induce&#xD;
      vasodilation in advanced pulmonary arterial hypertension (PAH) but also inhibit platelets,&#xD;
      increasing patients' bleeding risk. The antiplatelet effects of different prostacyclin&#xD;
      analogues have never been compared head-to-head. The goal of the PAPAYA (Platelet Reactivity&#xD;
      and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension) trial is(i) to&#xD;
      compare platelet function (platelet reactivity, extracellular vesicles concentration and&#xD;
      thrombus formation) in patients with PAH treated with prostacyclin analogues on top of&#xD;
      endothelin receptor antagonists (ERA) and/or phosphodiesterase type 5 inhibitors (PDE5i) and&#xD;
      patients treated only with ERA and PDE5i, and (ii) to compare the antiplatelet effect of&#xD;
      different prostacyclin analogues.&#xD;
&#xD;
      Venous blood will be collected from patients treated with prostacyclin analogues (study&#xD;
      group; n=40) and patients treated with ERA or PDE5i (control group; n=40). Platelet&#xD;
      reactivity will be analysed in whole blood by impedance aggregometry using arachidonic acid,&#xD;
      adenosine diphosphate and thrombin receptor-activating peptide as agonists. Concentrations of&#xD;
      extracellular vesicles from all platelets (CD61+), activated platelets (CD62P+), leukocytes&#xD;
      (CD45+) and endothelial cells (CD146+) will be analysed in platelet-depleted plasma using&#xD;
      flow cytometry (A-60 Micro). Platelet-rich thrombus formation will be measured using whole&#xD;
      blood perfusion system. The study will determine the antiplatelet effect of prostacyclin&#xD;
      analogues and compare different prostacyclin analogues head-to-head to identify the best&#xD;
      drugs to use in case of thrombosis or bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">September 23, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>July 5, 2017 - November 30, 2019</time_frame>
    <description>Difference in platelet reactivity between patients treated with prostacyclin analogues and treated with ERA and/ or PDE5-i, assessed using impedance aggregometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of extracellular vesicles from platelets, leukocytes and endothelial cells</measure>
    <time_frame>July 5, 2017 - November 30, 2019</time_frame>
    <description>Differences in concentration of extracellular vesicles from platelets, leukocytes and endothelial cells between patients treated with prostacyclin analogues and treated with ERA and/ or PDE5i, assessed using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet-rich thrombus formation parameters</measure>
    <time_frame>July 5, 2017 - November 30, 2019</time_frame>
    <description>Differences in platelet-rich thrombus formation parameters between patients treated with prostacyclin analogues and treated with ERA and/ or PDE5i, assessed using whole-blood flow-chamber perfusion system</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients were eligible for enrolment if they (i) had PAH diagnosed according to the&#xD;
        criteria of European Society of Cardiology and European Respiratory Society, confirmed&#xD;
        during right heart catheterization, (ii) were treated with prostacyclin analogues on top of&#xD;
        other drugs (study group) or only other drugs (ERA and PDE-5i; control group) for at least&#xD;
        1 month.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent to participate in the study&#xD;
&#xD;
          -  Pulmonary arterial hypertension confirmed with right heart catheterization&#xD;
&#xD;
          -  Treatment with prostacyclin analogues (epoprostenol, treprostinil, iloprost) - study&#xD;
             group&#xD;
&#xD;
          -  Treatment with endothelin receptor antagonists and phosphodiesterase type 5 inhibitors&#xD;
             - control group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known coagulopathy&#xD;
&#xD;
          -  Active pathological bleeding&#xD;
&#xD;
          -  Known history of bleeding disorder&#xD;
&#xD;
          -  Severe thrombocytopenia (platelet count &lt; 50,000/Î¼L )&#xD;
&#xD;
          -  Need for antiplatelet therapy with acetylsalicylic acid or P2Y12 antagonists&#xD;
&#xD;
          -  Severe chronic renal failure (estimated glomerular filtration rate &lt; 30 mL/min)&#xD;
&#xD;
          -  Severe liver insufficiency (Child-Pugh class C)&#xD;
&#xD;
          -  Known pregnancy, breast-feeding, or intention to become pregnant during the study&#xD;
             period&#xD;
&#xD;
          -  Study drug intolerance&#xD;
&#xD;
          -  Participation in any previous study with prostacyclin analogues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Education Medical, European Health Centre Otwock</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostacyclin analogues</keyword>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>extracellular vesicles</keyword>
  <keyword>thrombus formation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

